Background

Nicolas Vachicouras is the co-founder and Chief Executive Officer of Neurosoft Bioelectronics, the Swiss neurotech company developing soft, stretchable cortical electrode arrays. He completed his PhD at EPFL in Prof. Stéphanie Lacour’s Laboratory for Soft Bioelectronic Interfaces in 2019, with a thesis titled “Soft microfabricated neural implants: a path towards translational implementation”.

Career

His doctoral work included a 2019 Science Translational Medicine paper, on which he was a co-first author, showing that microstructured thin-film electrodes could serve as soft auditory brainstem implants. He spun Neurosoft out of Lacour’s laboratory in 2020.

Neurosoft Bioelectronics

Vachicouras co-founded Neurosoft Bioelectronics in 2020 together with Ludovic Serex, Florian Fallegger, and Prof. Stéphanie Lacour. The company is headquartered at Campus Biotech Geneva and is commercialising the 64-channel soft, stretchable cortical electrode platform developed in Lacour’s lab. Neurosoft’s electrodes are 1,000 to 100,000 times softer than the materials used in other flexible neural interfaces, and the platform has been tested in 10 patients across two ongoing clinical trials at UTHealth Houston and UMC Utrecht for epilepsy surgery guidance, with severe tinnitus as the second target indication.

In May 2026, Vachicouras led Neurosoft to close a $7.5 million oversubscribed seed round led by Skybound Venture Capital, bringing total funding past $20 million. The round was Skybound’s inaugural portfolio investment.